Two biotech stocks where Goldman Sachs now sees around 50% upside potential!
Reading Time: 3 minutes
We see the biotech AI revolution as one of the next major innovation drivers in the healthcare sector. With Medpace, BB Biotech, and Thermo Fisher, we are positioned in the model portfolios. We avoid direct R&D risk. For those who are not bothered by this, pay attention to the new favorites from Goldman Sachs. The research firm is resuming coverage of Tarsus Pharmaceuticals and Jazz Pharmaceuticals with Buy ratings. The price targets imply an average upside potential of nearly 50%. Tarsus: XDEMVY is growing towards blockbuster status – Goldman...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
